Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ASTRAZENECA-PLC-4000930/news/IMFINZI-durvalumab-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-w-46444924/?utm_source=whatsapp&utm_medium=social&utm_campaign=share